{
  "legislationId": "119_HR_8339",
  "lastUpdate": "2026-04-23T11:25:09.927Z",
  "history": [
    {
      "timestamp": "2026-04-23T11:25:09.927Z",
      "source_url": "https://www.congress.gov/119/bills/hr8339/BILLS-119hr8339ih.htm",
      "model": "gemini-flash-lite-latest",
      "prompt_sent": "\nROLE: Fact Checker.\nZADANIE: Porównaj SOURCE (oryginał) i SUMMARY (streszczenie przygotowane przez inne AI).\n\nTwoim celem jest wykrycie \"ZMYŚLONYCH KONKRETÓW\" (Fabricated Entities) w SUMMARY.\n\nSOURCE:\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8339 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8339 To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 16, 2026 Ms. Matsui (for herself, Mr. Crenshaw, Ms. Schrier, and Mrs. Hinson) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Drug Origin Transparency Act of 2026''. SEC. 2. ENHANCED DRUG MANUFACTURING AMOUNT INFORMATION REPORTING. (a) In General.--Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(j)(3)) is amended-- (1) in subparagraph (A), by adding ``or (2)'' after ``paragraph (1)''; and (2) by adding at the end the following: ``(C) Each report submitted pursuant to subparagraph (A) with respect to a drug shall-- ``(i) include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as-- ``(I) the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and ``(II) the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in- process material from each such identified supplier; and ``(ii) be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year. ``(D) Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)).''. (b) Conforming Amendment.--Section 510(j)(3)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 510(j)(3)(B)) is amended by striking ``subparagraph (A)'' and inserting ``this paragraph''. SEC. 3. REQUIRE DRUG LABELING TO INCLUDE ORIGINAL MANUFACTURER AND SUPPLY CHAIN INFORMATION. Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended-- (1) in paragraph (b)-- (A) by striking ``(b) If in a package'' and inserting ``(b)(1) If in a package''; (B) by striking ``a label containing (1) the name and place'' and inserting ``a label containing-- ``(A) the name and place''; (C) by striking ``or distributor; and (2) an accurate statement'' and inserting ``or distributor; and ``(B) an accurate statement''; (D) by striking ``under clause (2) of this paragraph'' and inserting ``under this clause''; and (E) by inserting at the end the following: ``(2)(A) Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements. ``(B) Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless any accompanying certificate of analysis contains the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient. ``(C) The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph.''; and (2) by inserting after paragraph (c) the following: ``(d)(1) Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of-- ``(A) the original manufacturer of each active pharmaceutical ingredient; ``(B) each manufacturer, if different from the original manufacturer; and ``(C) the packer or distributor, if any. ``(2) The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means.''. <all>\n\nSUMMARY TO EVALUATE:\nTitle: Drug Origin Transparency Act of 2026\nSummary: This act requires drug manufacturers to disclose the exact sources of their ingredients and the identity of the original manufacturer on labels. It aims to give citizens more clarity about where their medications come from and how they are made.\nKey Points: Drug labels must now include the name and location of the original manufacturer., Pharmaceutical companies are required to report ingredient supplier information up to four times a year., Mandatory disclosure of the sources for all active pharmaceutical ingredients and materials., Increased transparency helps monitor and ensure the safety of the drug supply chain.\n\nZASADY OCENY:\n1. Sprawdź wszystkie LICZBY, DATY i KWOTY w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n2. Sprawdź wszystkie NAZWISKA, ORGANIZACJE i MIEJSCA w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n3. Sprawdź wszystkie konkretne DZIAŁANIA PRAWNE . Jeśli tego mechanizmu nie ma w SOURCE -> is_valid: false.\n\nWAŻNE: Abstrakcyjne pojęcia (np. \"transparentność\", \"zaufanie\") są dozwolone jako wnioski.\n\nOUTPUT (JSON):\n{\n  \"is_valid\": true/false,\n  \"issue\": \"fabricated_entity\" / \"contradiction\" / \"none\"\n}\n\nWYMAGANIA FORMATOWANIA:\n1. Odpowiedz WYŁĄCZNIE surowym obiektem JSON.\n2. NIE używaj bloków kodu Markdown.\n3. NIE dodawaj żadnych wstępów ani wyjaśnień przed ani po JSONie.\n4. JSON musi być poprawny i gotowy do parsowania.\n\n",
      "ai_response_raw": "{\n  \"is_valid\": true,\n  \"issue\": \"none\"\n}"
    },
    {
      "timestamp": "2026-04-23T11:12:47.999Z",
      "source_url": "https://www.congress.gov/119/bills/hr8339/BILLS-119hr8339ih.htm",
      "model": "gemini-flash-latest",
      "prompt_sent": "\nJesteś ekspertem od prawa Stanów Zjednoczonych, który ma za zadanie analizować dokumenty ustaw, uchwał oraz innych dokumentów legislacyjnych, a następnie przygotowywać z nich informacje w przystępny sposób dla obywateli. Twoim celem jest przedstawienie informacji tak, aby obywatele mogli sami ocenić wpływ legislacji na ich życie, nawet bez posiadania specjalistycznej wiedzy legislacyjnej. Skup się na faktach i obiektywnych skutkach wprowadzanych zmian, unikając wartościowania i osobistych opinii. Wszelki żargon prawny jest zabroniony. Prezentuj informacje w jasny, zwięzły i angażujący sposób, tak aby były zrozumiałe dla osoby bez wykształcenia prawniczego. Unikaj długich, złożonych zdań. Zamiast pisać \"projekt ma na celu nowelizację kodeksu podatkowego...\", napisz \"Zmiany w podatkach: nowe ulgi i obowiązki dla...\". Kontynuuj swoją pracę, dopóki nie rozwiążesz swojego zadania. Jeśli nie masz pewności co do generowanej treści, przeanalizuj dokument ponownie – nie zgaduj. Rozplanuj dobrze swoje zadanie przed przystąpieniem do niego. W podsumowaniu i kluczowych punktach, jeśli to możliwe i uzasadnione, podkreśl, jakie konkretne korzyści lub skutki (pozytywne lub negatywne) wprowadza ustawa dla życia codziennego obywateli, ich praw i obowiązków, finansów osobistych, bezpieczeństwa i innych ważnych kwestii (np. kategorycznych zakazów i nakazów czy najważniejszych konkretnych alokacji finansowych i terytorialnych).\n\nTwoja odpowiedź MUSI być w formacie JSON - i zawierać następujące klucze.\nZanim zwrócisz odpowiedź, dokładnie zweryfikuj, czy cała struktura JSON jest w 100% poprawna, włącznie ze wszystkimi przecinkami, nawiasami klamrowymi, kwadratowymi oraz cudzysłowami. Błędny JSON jest nieakceptowalny i uniemożliwi przetworzenie Twojej pracy.\n\nPrzeanalizuj dokładnie poniższy tekst dokumentu prawnego. To jest treść, na podstawie której masz wygenerować podsumowanie i kluczowe punkty:\n--- POCZĄTEK DOKUMENTU ---\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8339 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8339 To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 16, 2026 Ms. Matsui (for herself, Mr. Crenshaw, Ms. Schrier, and Mrs. Hinson) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Drug Origin Transparency Act of 2026''. SEC. 2. ENHANCED DRUG MANUFACTURING AMOUNT INFORMATION REPORTING. (a) In General.--Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(j)(3)) is amended-- (1) in subparagraph (A), by adding ``or (2)'' after ``paragraph (1)''; and (2) by adding at the end the following: ``(C) Each report submitted pursuant to subparagraph (A) with respect to a drug shall-- ``(i) include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as-- ``(I) the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and ``(II) the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in- process material from each such identified supplier; and ``(ii) be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year. ``(D) Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)).''. (b) Conforming Amendment.--Section 510(j)(3)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 510(j)(3)(B)) is amended by striking ``subparagraph (A)'' and inserting ``this paragraph''. SEC. 3. REQUIRE DRUG LABELING TO INCLUDE ORIGINAL MANUFACTURER AND SUPPLY CHAIN INFORMATION. Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended-- (1) in paragraph (b)-- (A) by striking ``(b) If in a package'' and inserting ``(b)(1) If in a package''; (B) by striking ``a label containing (1) the name and place'' and inserting ``a label containing-- ``(A) the name and place''; (C) by striking ``or distributor; and (2) an accurate statement'' and inserting ``or distributor; and ``(B) an accurate statement''; (D) by striking ``under clause (2) of this paragraph'' and inserting ``under this clause''; and (E) by inserting at the end the following: ``(2)(A) Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements. ``(B) Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless any accompanying certificate of analysis contains the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient. ``(C) The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph.''; and (2) by inserting after paragraph (c) the following: ``(d)(1) Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of-- ``(A) the original manufacturer of each active pharmaceutical ingredient; ``(B) each manufacturer, if different from the original manufacturer; and ``(C) the packer or distributor, if any. ``(2) The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means.''. <all>\n--- KONIEC DOKUMENTU ---\n\nPAMIĘTAJ: Twoja odpowiedź MUSI być wyłącznie poprawnym obiektem JSON. Nie dodawaj żadnych dodatkowych znaków, komentarzy ani tekstu przed znacznikiem '{' ani po znaczniku '}'. Cała odpowiedź musi być parsowalna jako JSON.\nNa podstawie POWYŻSZEGO dokumentu, wypełnij poniższą strukturę JSON:\nOto struktura JSON, której oczekuję (wypełnij ją treścią):\n{\n  \"pl_ai_title\": \"Nowy, krótki tytuł dla aktu prawnego po polsku, oddający sedno wprowadzanych zmian (np. maksymalnie 10-12 słów).\",\n  \"pl_summary\": \"2-3 zdania zwięzłego podsumowania treści aktu prawnego po polsku, napisane z perspektywy wpływu na życie codzienne obywateli.\",\n  \"pl_key_points\": [\n    \"Pierwszy krótki punkt po polsku dotyczący najważniejszych wprowadzanych rozwiązań lub zmian.\",\n    \"Drugi krótki punkt po polsku...\"\n  ],\n  \"eng_ai_title\": \"A new, short title for the legal act in English, capturing the essence of the changes (e.g., max 10-12 words).\",\n  \"eng_summary\": \"2-3 sentences summarizing the legal act in English, from the perspective of its impact on citizens' daily lives.\",\n  \"eng_key_points\": [\n    \"First short bullet point in English regarding the most important solutions or changes being introduced.\",\n    \"Second short bullet point in English...\"\n  ],\n  \"de_ai_title\": \"Ein neuer, kurzer Titel für das Rechtsdokument auf Deutsch, der den Kern der Änderungen erfasst (z.B. max. 10-12 Wörter).\",\n  \"de_summary\": \"2-3 Sätze Zusammenfassung des Rechtsdokuments auf Deutsch, aus der Perspektive seiner Auswirkungen auf das tägliche Leben der Bürger.\",\n  \"de_key_points\": [\n    \"Erster kurzer Stichpunkt auf Deutsch zu den wichtigsten eingeführten Lösungen oder Änderungen.\",\n    \"Zweiter kurzer Stichpunkt auf Deutsch...\"\n  ],\n  \"fr_ai_title\": \"Un nouveau titre court pour l'acte juridique en français, saisissant l'essence des changements (par exemple, 10-12 mots maximum).\",\n  \"fr_summary\": \"Résumé de 2-3 phrases de l'acte juridique en français, du point de vue de son impact sur la vie quotidienne des citoyens.\",\n  \"fr_key_points\": [\n    \"Premier court point en français concernant les solutions ou changements les plus importants introduits.\",\n    \"Deuxième court point en français...\"\n  ],\n  \"es_ai_title\": \"Un nuevo título breve para el acto jurídico en español, que recoja la esencia de los cambios (por ejemplo, máximo 10-12 palabras).\",\n  \"es_summary\": \"Resumen de 2-3 frases del acto jurídico en español, desde la perspectiva de su impacto en la vida cotidiana de los ciudadanos.\",\n  \"es_key_points\": [\n    \"Primer punto breve en español sobre las soluciones o cambios más importantes que se introducen.\",\n    \"Segundo punto breve en español...\"\n  ],\n  \"it_ai_title\": \"Un nuovo titolo breve per l'atto giuridico in italiano, che colga l'essenza delle modifiche (ad es. massimo 10-12 parole).\",\n  \"it_summary\": \"Riepilogo di 2-3 frasi dell'atto giuridico in italiano, dal punto di vista del suo impatto sulla vita quotidiana dei cittadini.\",\n  \"it_key_points\": [\n    \"Primo breve punto in italiano riguardante le soluzioni o le modifiche più importanti introdotte.\",\n    \"Secondo breve punto in italiano...\"\n  ],\n  \"nl_ai_title\": \"Een nieuwe, korte titel voor de rechtshandeling in het Nederlands, die de essentie van de wijzigingen weergeeft (bijv. max. 10-12 woorden).\",\n  \"nl_summary\": \"Samenvatting van 2-3 zinnen van de rechtshandeling in het Nederlands, vanuit het perspectief van de impact op het dagelijks leven van burgers.\",\n  \"nl_key_points\": [\n    \"Eerste korte punt in het Nederlands betreffende de belangrijkste geïntroduceerde oplossingen of wijzigingen.\",\n    \"Tweede korte punt in het Nederlands...\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Resumo de 2-3 frases do ato jurídico em português, na perspetiva do seu impacto na vida quotidiana dos cidadãos.\",\n  \"pt_key_points\": [\n    \"Primeiro ponto curto em português sobre as soluções ou alterações mais importantes introduzidas.\",\n    \"Segundo ponto curto em português...\"\n  ],\n  \"category\": [\"Categorize the document into one category by default, based on the field it primarily concerns. Choose up to 3 if the document also touches upon SIGNIFICANT issues from other categories. You MUST select categories ONLY from the following list: Health, Education, Family, Taxes, Labor, Security, Environment, Courts and Law, Transport, Benefits, Real Estate, Media and Culture, Local Government, Migration, Agriculture, Public Investments, Informatization, Economy. If the document does not definitively fit any of these, you MUST use \"Other\". If you use \"Other\", it should be the ONLY category selected. Do NOT invent new categories. The response must be an array of strings, e.g., [\"Taxes\", \"Family\"].\"]\n}\n\n",
      "ai_response_raw": "{\n  \"pl_ai_title\": \"Ustawa o przejrzystości pochodzenia leków z 2026 roku\",\n  \"pl_summary\": \"Ustawa wprowadza obowiązek informowania o tym, skąd dokładnie pochodzą składniki leków oraz kto jest ich pierwotnym producentem. Dzięki temu pacjenci i lekarze będą mieli lepszą wiedzę o jakości i źródle stosowanych medykamentów.\",\n  \"pl_key_points\": [\n    \"Etykiety leków muszą teraz zawierać nazwę i lokalizację ich pierwotnego producenta.\",\n    \"Firmy farmaceutyczne będą musiały częściej (do 4 razy w roku) zgłaszać dane o swoich dostawcach.\",\n    \"Wprowadzono obowiązek ujawniania źródeł wszystkich aktywnych składników użytych do produkcji leku.\",\n    \"Zwiększona przejrzystość ma pomóc w lepszym monitorowaniu bezpieczeństwa łańcucha dostaw leków.\"\n  ],\n  \"eng_ai_title\": \"Drug Origin Transparency Act of 2026\",\n  \"eng_summary\": \"This act requires drug manufacturers to disclose the exact sources of their ingredients and the identity of the original manufacturer on labels. It aims to give citizens more clarity about where their medications come from and how they are made.\",\n  \"eng_key_points\": [\n    \"Drug labels must now include the name and location of the original manufacturer.\",\n    \"Pharmaceutical companies are required to report ingredient supplier information up to four times a year.\",\n    \"Mandatory disclosure of the sources for all active pharmaceutical ingredients and materials.\",\n    \"Increased transparency helps monitor and ensure the safety of the drug supply chain.\"\n  ],\n  \"de_ai_title\": \"Gesetz zur Transparenz der Arzneimittelherkunft von 2026\",\n  \"de_summary\": \"Dieses Gesetz verpflichtet Arzneimittelhersteller, die genaue Herkunft ihrer Inhaltsstoffe und den ursprünglichen Hersteller auf den Etiketten anzugeben. Bürger erhalten so mehr Klarheit darüber, woher ihre Medikamente stammen.\",\n  \"de_key_points\": [\n    \"Arzneimitteletiketten müssen nun den Namen und Standort des ursprünglichen Herstellers enthalten.\",\n    \"Pharmaunternehmen müssen bis zu viermal pro Jahr Informationen über ihre Wirkstofflieferanten melden.\",\n    \"Offenlegungspflicht für die Quellen aller aktiven pharmazeutischen Bestandteile.\",\n    \"Erhöhte Transparenz zur besseren Überwachung der Sicherheit in der Lieferkette.\"\n  ],\n  \"fr_ai_title\": \"Loi de 2026 sur la transparence de l'origine des médicaments\",\n  \"fr_summary\": \"Cette loi oblige les fabricants de médicaments à divulguer les sources exactes de leurs ingrédients et l'identité du fabricant d'origine sur les étiquettes. Elle permet aux citoyens de mieux connaître la provenance de leurs traitements.\",\n  \"fr_key_points\": [\n    \"Les étiquettes des médicaments doivent désormais mentionner le nom et le lieu du fabricant d'origine.\",\n    \"Les entreprises pharmaceutiques doivent déclarer leurs fournisseurs d'ingrédients jusqu'à quatre fois par an.\",\n    \"Divulgation obligatoire des sources de tous les principes actifs utilisés dans la fabrication.\",\n    \"Une transparence accrue pour mieux garantir la sécurité de la chaîne d'approvisionnement en médicaments.\"\n  ],\n  \"es_ai_title\": \"Ley de Transparencia del Origen de los Medicamentos de 2026\",\n  \"es_summary\": \"Esta ley exige que los fabricantes de medicamentos revelen las fuentes exactas de sus ingredientes y la identidad del fabricante original en las etiquetas. Los ciudadanos tendrán más información sobre la procedencia de sus medicinas.\",\n  \"es_key_points\": [\n    \"Las etiquetas de los medicamentos deben incluir ahora el nombre y la ubicación del fabricante original.\",\n    \"Las farmacéuticas deben informar sobre sus proveedores de ingredientes hasta cuatro veces al año.\",\n    \"Divulgación obligatoria de las fuentes de todos los ingredientes farmacéuticos activos.\",\n    \"Mayor transparencia para supervisar y garantizar la seguridad de la cadena de suministro de fármacos.\"\n  ],\n  \"it_ai_title\": \"Legge sulla trasparenza dell'origine dei farmaci del 2026\",\n  \"it_summary\": \"Questa legge impone ai produttori di farmaci di indicare sulle etichette le fonti esatte degli ingredienti e l'identità del produttore originale. I cittadini avranno maggiore chiarezza sulla provenienza dei loro medicinali.\",\n  \"it_key_points\": [\n    \"Le etichette dei farmaci devono ora riportare il nome e la sede del produttore originale.\",\n    \"Le aziende farmaceutiche sono tenute a comunicare i dati sui fornitori di ingredienti fino a quattro volte l'anno.\",\n    \"Obbligo di divulgare le fonti di tutti i principi attivi utilizzati nella produzione.\",\n    \"Maggiore trasparenza per monitorare e garantire la sicurezza della catena di fornitura dei medicinali.\"\n  ],\n  \"nl_ai_title\": \"Wet transparantie herkomst geneesmiddelen van 2026\",\n  \"nl_summary\": \"Deze wet verplicht medicijnfabrikanten om de exacte bronnen van hun ingrediënten en de identiteit van de oorspronkelijke fabrikant op etiketten te vermelden. Burgers krijgen hierdoor meer inzicht in waar hun medicijnen vandaan komen.\",\n  \"nl_key_points\": [\n    \"Medicijnetiketten moeten voortaan de naam en locatie van de oorspronkelijke fabrikant bevatten.\",\n    \"Farmaceutische bedrijven moeten tot vier keer per jaar informatie over hun ingrediëntenleveranciers rapporteren.\",\n    \"Verplichte openbaarmaking van de bronnen van alle actieve farmaceutische bestanddelen.\",\n    \"Verhoogde transparantie om de veiligheid van de toeleveringsketen van medicijnen te bewaken.\"\n  ],\n  \"pt_ai_title\": \"Lei de Transparência da Origem dos Medicamentos de 2026\",\n  \"pt_summary\": \"Esta lei exige que os fabricantes de medicamentos divulguem as fontes exatas dos seus ingredientes e a identidade do fabricante original nos rótulos. Os cidadãos terão mais clareza sobre a proveniência dos seus medicamentos.\",\n  \"pt_key_points\": [\n    \"Os rótulos dos medicamentos devem agora incluir o nome e a localização do fabricante original.\",\n    \"As empresas farmacêuticas devem comunicar informações sobre fornecedores de ingredientes até quatro vezes por ano.\",\n    \"Divulgação obrigatória das fontes de todos os ingredientes farmacêuticos ativos.\",\n    \"Maior transparência para monitorizar e garantir a segurança da cadeia de abastecimento de medicamentos.\"\n  ],\n  \"category\": [\"Health\", \"Economy\"]\n}"
    }
  ]
}